-transparent.png){kind=logo}
Fourteen patients with measurable non-small cell lung cancer, who had not received prior chemotherapy, were treated with the anthracene derivative bisantrene. Although treatment was well tolerated, no antitumor activity was observed and all but two patients demonstrated disease progression before the third course of chemotherapy. We conclude that bisantrene does not have significant antitumor activity in non-small cell lung cancer.
Related Publications
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
June 1985,
Cancer treatment reports,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
June 1984,
Cancer treatment reports,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
January 1985,
Investigational new drugs,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
October 1982,
Cancer treatment reports,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
June 1983,
Cancer treatment reports,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
January 1981,
Cancer clinical trials,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
April 1979,
Cancer treatment reports,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
August 1979,
Cancer treatment reports,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
January 1988,
Medical and pediatric oncology,
R Feld, and
W K Evans, and
F A Shepherd, and
G Deboer, and
B Ottema
March 1983,
Cancer treatment reports,
